Novartis AG ADR (NVS)vsNexgel Inc (NXGL)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
NXGL
Nexgel Inc
$0.29
+0.34%
HEALTHCARE · Cap: $3.09M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 469718% more annual revenue ($56.69B vs $12.07M). NVS leads profitability with a 22.5% profit margin vs -51.3%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
NXGL
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Margin of Safety
+43.8%
Fair Value
$2.49
Current Price
$0.29
$2.20 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Revenue surging 27.8% year-over-year
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
ROE of -80.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : NXGL
The strongest argument for NXGL centers on Price/Book, Revenue Growth. Revenue growth of 27.8% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : NXGL
The primary concerns for NXGL are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.51 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a value stock while NXGL is a growth play — different risk/reward profiles.
NXGL carries more volatility with a beta of 0.75 — expect wider price swings.
NXGL is growing revenue faster at 27.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 39/100), backed by strong 22.5% margins. NXGL offers better value entry with a 43.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Nexgel Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
NEXGEL, Inc. manufactures aqueous, electron beam crosslinked, high water content hydrogels and polymeric gels. The company is headquartered in Langhorne, Pennsylvania.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?